Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects

Paul Chan, Brian Tomlinson, Ching Bing Lee, Wen Harn Pan, Ying Shiung Lee

Research output: Contribution to journalArticle

22 Citations (Scopus)


We undertook this prospective double-blind, placebo-controlled study to evaluate the efficacy and safety of low-dose (15 mg) pravastatin in elderly hypercholesterolemic hypertensive subjects with concurrent antihypertensive treatment and to determine whether fasting hyperinsulinemia could also be improved. At three hypertension and lipid clinics of two medical centers, 96 elderly (49 women, 47 men) ambulatory subjects were randomized to active treatment or placebo for 12 months after a 3-month single-blind lead in period. Hypertensive subjects with plasma total cholesterol levels of at least 6.47 mmol/L (250 mg/dL) and triglyceride levels less than 3.39 mmol/L (300 mg/dL) were treated with 15 mg pravastatin for 12 months after receiving 3 mouths of the American Heart Association step 1 diet. Lipid, glucose, and fasting insulin levels were measured; clinical laboratory tests included liver function and creatine kinase determinations. After 12 months of pravastatin therapy, plasma total cholesterol concentration decreased by 25.1% (from a mean of 7.29 to 5.47 mmol/L, P

Original languageEnglish
Pages (from-to)647-651
Number of pages5
Issue number4
Publication statusPublished - Oct 1996
Externally publishedYes



  • cholesterol
  • hydroxymethylglutaryl CoA reductases
  • hyperinsulinism
  • pravastatin

ASJC Scopus subject areas

  • Internal Medicine

Cite this